Skip to main content
Premium Trial:

Request an Annual Quote

Toni Schuh, Thomas Baer, Richard Kniss, Janet Thornton, Ewan Birney, Thomas Theriault

Premium

Toni Schuh will serve as the new CEO of Arcturus Bioscience, the company said this week. Schuh recently stepped down as CEO of Sequenom. Arcturus also said that Schuh will be elected to its board of directors.

Schuh previously held positions at Helm and Fisions Pharmaceuticals. He holds a PhD in medicinal chemistry from the University of Bonn.

Schuh succeeds former CEO and founder Thomas Baer, who resigned in late 2004 to serve as a consulting professor in the Applied Physics department at Stanford University.

Baer continues to serve as a director of Arcturus. Richard Kniss, who has served as a member of the Arcturus Board since January 2002, will be appointed non-executive chairman, the company said.


Janet Thornton has won this year’s senior scientist accomplishment award and Ewan Birney the Overton prize from the International Society for Computational Biology, ISCB and the European Bioinformatics Institute said last week.

Thornton, who has been director of EBI since 2001 as well as coordinator of the BioSapiens network of excellence, receives the award for outstanding and seminal research contributions to the field of structural bioinformatics. She is also the founding chief scientific officer of Inpharmatica.

Birney is honored for his work on Ensembl, the genome browser. He has been a coordinator of EBI’s contributions to Ensembl since 2000. He is also a co-leader of the open-source project Bioperl and president of the Open Bioinformatics Foundation. Birney holds an undergraduate degree in biochemistry from Oxford University and obtained a PhD in gene prediction from the Wellcome Trust Sanger Institute.


Genitope has appointed Thomas Theriault as vice president of research. He joins Genitope after nine years at Incyte. Prior to Incyte, Theriault co-founded Combion in 1994, a privately held DNA microarray company focused on genetic and genomic applications, where he also served as director of research until the company was acquired by Incyte in 1996. He received his PhD in biophysical chemistry from Stanford University and his BA in chemistry from Dartmouth College.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.